**Supplemental TABLE 2.** Cardiovascular-related adverse events, on-therapy period

|  |  |  |
| --- | --- | --- |
|  | **Study 1030 (N=281)** | **Study 1031 (N=268)** |
| Sinus bradycardia | 1 (0.4) | 1 (0.4) |
| Right bundle branch block  | 1 (0.4) | 0 |
| Nodal arrhythmia | 1 (0.4) | 0 |
| Palpitations | 2 (0.7) | 0 |
| Tachycardia  | 1 (0.4) | 1 (0.4) |
| Blood pressure abnormal | 1 (0.4) | 0 |
| Blood pressure increased  | 1 (0.4) | 6 (2.2) |
| Orthostatic blood pressure abnormal | 2 (0.7) | 0 |
| Orthostatic blood pressure increased | 0 | 1 (0.4) |
| Systolic blood pressure increased | 2 (0.7) | 1 (0.4) |
| Heart rate increased  | 2 (0.7) | 1 (0.4) |
| Orthostatic hypotension  | 0 | 1 (0.4) |
| Orthostatic heart rate response increased | 2 (0.7) | 0 |
| Pulse abnormal | 3 (1.1) | 0 |

TEAEs, treatment-emergent adverse events.